Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

177.53 +1.96 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,833,633
Open 177.00
Bid (Size) 168.20 (1)
Ask (Size) 172.40 (2)
Prev. Close 175.57
Today's Range 175.78 - 179.04
52wk Range 125.82 - 331.65
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024
PODD stock results show that Insulet beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire

Performance

YTD
-15.10%
-15.10%
1 Month
-0.27%
-0.27%
3 Month
-9.72%
-9.72%
6 Month
+16.12%
+16.12%
1 Year
-45.01%
-45.01%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
4 Analysts Assess Insulet: What You Need To Know
Via Benzinga
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
From Insulet Corporation
Via Business Wire
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
7 Stable Stocks for 50% Returns by Early 2025
Via InvestorPlace
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
From Insulet Corporation
Via Business Wire
Analyst Scoreboard: 5 Ratings For Insulet
Via Benzinga
Insulet: Q4 Earnings Insights
Via Benzinga
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Via Talk Markets
5 Stocks To Buy On The Dip To Gain From The Wall Street Rally
Via Talk Markets
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
From Insulet Corporation
Via Business Wire
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Are These 5 Undervalued Stocks Ready to Break Out?
Via MarketBeat
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
From Insulet Corporation
Via Business Wire
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Insulet Corporation
Via Business Wire
Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Via Benzinga
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
DexCom: A Winner In Diabetes Management
Via Talk Markets
Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate Cuts
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.